Le Lézard
Classified in: Health
Subject: SVY

Singapore Pharmaceutical Market 2012-2017 & 2018-2022


DUBLIN, Oct. 16, 2018 /PRNewswire/ --

The "Singapore Pharmaceutical Market Outlook to 2022 - by Prescription & OTC Drugs and by Patented & Generic Drugs" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Singapore Pharmaceutical Market Outlook to 2022 covers aspects such as pharmaceutical market segment (by Prescription & OTC Drugs, by Patented & Generic Drugs), and competitive landscape of major players. The report concludes with market projection for future and analyst recommendations highlighting the major opportunities and cautions.

Singapore Pharmaceutical market can be characterized by the presence of best-in-class infrastructure, integrated and advanced hubs for pharmaceutical manufacturing and research and access to regional markets and skilled workforce. Singapore Pharmaceutical market has registered an increase in the revenue during the period 2012-2017. Many leading biomedical companies such as AbbVie, Pfizer, Ferring Pharmaceuticals and others have selected Singapore as their global manufacturing base.

Singapore OTC market increased at a double digit CAGR during 2012-2017. The market is driven by increasing number of people taking self-medication. Further, increased focus on R&D efforts has led to better focus on the advancement of innovative over-the-counter and consumer health drugs.

Singapore pharmaceutical market is expected to grow at a single digit CAGR during 2017-2018 driven by universal access to health insurance and world-class biomedical research facilities.

The best in class research and manufacturing infrastructure will continue to attract foreign investment in the country. For instance, Japan's Chugai Pharmaceutical, which operates satellite labs throughout Asia, has plans to invest USD 355 million by 2021, to accelerate its research and development (R&D) capabilities in Singapore.

Key Topics Covered:

1. Research Methodology

2. Singapore Pharmaceutical Market - Executive Summary

3. Singapore Pharmaceutical Ecosystem

4. Singapore Healthcare System

5. Singapore Healthcare Key Metrics

6. Comparative Analysis with Other Asian Countries

7. Regulatory Bodies in Singapore Healthcare System

8. Singapore Pharmaceutical Market

9. Singapore Pharmaceutical Market Segmentation

10. Singapore Pharmaceutical Market Recent Developments & Growth Drivers

11. Singapore Pharmaceutical Market- Restraints

12. Government Regulations for Singapore Pharmaceutical Market

13. New Drug Approvals in Singapore, 2017

14. Singapore Pharmaceutical Market Competition Analysis

15. Singapore Pharmaceutical Market: Future Outlook and Projections

16. Snapshot on Singapore Vitamin and Dietary Supplement Market

17. Snapshot for Singapore Animal Healthcare

18. Snapshot for Singapore Biopharmaceutical Market

19. Singapore Pharmaceutical Market - Analyst Recommendations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/zh972c/singapore?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 01:24
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...

at 01:17
Essity's Interim Report, Quarter 1, 2024
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
Few small SUVs excel in new IIHS front crash prevention test
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential expands globally to Oceania, Asia and the Gulf
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research Statement on Co-Founder and Chairman Dr. Stephen Harrison
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

More news about Health...


News published on and distributed by: